NexImmune, Inc. Email Format

Biotechnology ResearchMaryland, United States51-200 Employees

NexImmune, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing T cell–based immunotherapies. Its lead programs address relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to more than three prior lines of therapy. The AIM technology builds nanoparticle constructs that act as synthetic dendritic cells to direct a specific T cell response, aiming for a potent and durable effect with reduced risk of off-target toxicities.

The AIM platform is described as adaptable across oncology, autoimmune disorders, and infectious diseases, indicating broad potential beyond a single indication. NexImmune is based in Gaithersburg, Maryland, and operates as a mid-sized biotechnology research company. The company's focus is on leveraging the body's own T cells to generate targeted immune responses.

Get verified NexImmune, Inc. emails free

Company overview Employee directory